文献速递类风湿关节炎

从阿达木单抗转换为沙利鲁单抗治疗类风湿关节炎的长期安全性与疗效:MONARCH开放标签扩展研究

Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension.
PubMed 文献 · RMD Open · 2019-10-18

MONARCH开放标签扩展研究评估了类风湿关节炎患者从阿达木单抗单药治疗转换为沙利鲁单抗单药治疗(200 mg 每2周皮下注射)的长期安全性与疗效。转换后前10周未出现非预期安全信号,第12周时47.1%/34.8%的患者DAS28-ESR/DAS28-CRP改善≥1.2;第24周达到低疾病活动度的转换患者中约70%在第36和48周维持。继续沙利鲁单抗治疗的患者安全性符合长期使用特征且获益持续。

要点

  • 从阿达木单抗转换为沙利鲁单抗单药治疗未出现非预期安全信号。
  • 转换后第12周即有疾病活动度改善,第48周改善接近继续治疗组。
  • 第24周达到低疾病活动度的转换患者中约70%在第36和48周维持。

核心结论

  • 开放标签扩展期间,从阿达木单抗转换为沙利鲁单抗单药治疗的患者未出现非预期安全问题,许多患者疾病活动度改善。
  • 继续沙利鲁单抗治疗的患者安全性符合长期使用特征,且获益持续。

研究设计与样本

  • MONARCH(NCT02332590)开放标签扩展研究,为期48周,患者接受沙利鲁单抗200 mg每2周皮下注射。
  • 共320/369例完成24周双盲期的患者进入开放标签扩展,其中155例从阿达木单抗转换,165例继续沙利鲁单抗治疗。

主要发现

  • 双盲期中,沙利鲁单抗或阿达木单抗单药治疗均显示疾病活动度有意义改善,沙利鲁单抗在改善体征、症状和躯体功能方面优于阿达木单抗。
  • 转换患者中,开放标签扩展第12周时47.1%/34.8%的患者DAS28-ESR/DAS28-CRP改善≥1.2。
  • 第24周达到CDAI低疾病活动度(≤10)或SDAI低疾病活动度(≤11)的转换患者中,70.7%/69.5%在第36和48周均维持CDAI/SDAI低疾病活动度。
  • 第24周达到CDAI≤2.8和SDAI≤3.3的转换患者比例至第48周持续增加。
  • 转换后的改善接近继续治疗组数值,包括评分≥正常参考值。

关键数值与推荐

  • 低疾病活动度定义:CDAI≤10;SDAI≤11。
  • DAS28改善阈值:变化≥1.2。
  • 沙利鲁单抗剂量:200 mg皮下注射每2周一次。

临床怎么用

  • 对于阿达木单抗单药治疗后的类风湿关节炎患者,可考虑转换为沙利鲁单抗单药治疗,转换后需关注前10周安全性。
  • 转换后疾病活动度可在12周内改善,达到低疾病活动度者多数可维持至48周。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Evaluate open-label sarilumab monotherapy in patients with rheumatoid arthritis switching from adalimumab monotherapy in MONARCH (NCT02332590); assess long-term safety and efficacy in patients continuing sarilumab during open-label extension (OLE). METHODS: During the 48-week OLE, patients received sarilumab 200 mg subcutaneously once every 2 weeks. Safety (March 2017 cut-off) and efficacy, including patient-reported outcomes, were evaluated. RESULTS: In the double-blind phase, patients receiving sarilumab or adalimumab monotherapy showed meaningful improvements in disease activity; sarilumab was superior to adalimumab for improving signs, symptoms and physical function. Overall, 320/369 patients completing the 24-week double-blind phase entered OLE (155 switched from adalimumab; 165 continued sarilumab). Sarilumab safety profile was consistent with previous reports. Treatment-emergent adverse events were similar between groups; no unexpected safety signals emerged in the first 10 weeks postswitch. Among switch patients, improvement in disease activity was evident at OLE week 12: 47.1%/34.8% had changes ≥1.2 in Disease Activity Score (28 joints) (DAS28)-erythrocyte sedimentation rate/DAS28-C-reactive protein. In switch patients achieving low disease activity (LDA: Clinical Disease Activity Index (CDAI) ≤10; Simplified Disease Activity Index (SDAI) ≤11) by OLE week 24, 70.7%/69.5% sustained CDAI/SDAI LDA at both OLE weeks 36 and 48. Proportions of switch patients achieving CDAI ≤2.8 and SDAI ≤3.3 by OLE week 24 increased through OLE week 48. Improvements postswitch approached continuation-group values, including scores ≥normative values. CONCLUSIONS: During this OLE, there were no unexpected safety issues in patients switching from adalimumab to sarilumab monotherapy, and disease activity improved in many patients. Patients continuing sarilumab reported safety consistent with prolonged use and had sustained benefit.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Burmester GR, Strand V, Rubbert-Roth A, et al. Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension. RMD Open. 2019. PMID: 31673415. doi:10.1136/rmdopen-2019-001017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。